Microscopic colitis: a missed diagnosis among patients with moderate to severe irritable bowel syndrome

2016 ◽  
Vol 52 (2) ◽  
pp. 173-177 ◽  
Author(s):  
Frank Hilpüsch ◽  
Peter Holger Johnsen ◽  
Rasmus Goll ◽  
Per Christian Valle ◽  
Sveinung Wergeland Sørbye ◽  
...  
2013 ◽  
Vol 46 (6) ◽  
pp. 671 ◽  
Author(s):  
Kang Hun Koh ◽  
Sang Wook Kim ◽  
So Young Lee ◽  
Hee Jung Lee ◽  
Hea Min Yu ◽  
...  

2012 ◽  
Vol 38 (1) ◽  
pp. 33-38 ◽  
Author(s):  
MA Rahman ◽  
ASMA Raihan ◽  
DS Ahamed ◽  
H Masud ◽  
ABM Safiullah ◽  
...  

Microscopic Colitis (MC) and diarrhea predominant irritable bowel syndrome (IBS-D) has almost similar clinical feature but MC is diagnosed by histologic criteria and IBS is diagnosed by symptombased criteria. There is ongoing debate about the importance of biopsies from endoscopically normal colonic mucosa in the investigation of patients with IBS-D. Aim of this study was to assess the prevalence of MC in patient with IBS-D and to determine the distribution of MC in the colon. This observational study was conducted in department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from January 2008 to December 2009. Patients were evaluated thoroughly & who meet Rome–II criteria with normal routine laboratory tests, were included in the study. Colonoscopy was done and biopsies were taken from the caecum, transverse colon, descending colon, and rectum. Out of total 60 patients, 22 had Lymphocytic Colitis (LC), 28 had nonspecific microscopic colitis (NSMC) and 10 had irritable bowel syndrome noninflamed (IBSNI). The distribution of LC was restricted to proximal colon in 15 patients, in the left colon in 2 patients and diffuses throughout the colon in 5 patients. There is considerable symptom overlap between the patients of IBS-D and patients with microscopic colitis. Without colonoscopic biopsy from multiple sites, possibility of MC cannot be excluded in patients with IBS-D and it can be said that clinical symptom based criteria for irritable bowel syndrome are not sufficient enough to rule out the diagnosis of microscopic colitis. DOI: http://dx.doi.org/10.3329/bmrcb.v38i1.10450 Bangladesh Med Res Counc Bull 2012; 38: 33-38


2015 ◽  
Vol 45 ◽  
pp. 393-397 ◽  
Author(s):  
Zahide ŞİMŞEK ◽  
Nazife Candan TUNCER ◽  
Hakan ALAGÖZLÜ ◽  
Fatih KARAAHMET ◽  
Şahin ÇOBAN ◽  
...  

2011 ◽  
Vol 140 (5) ◽  
pp. S-289
Author(s):  
Rami F. Abboud ◽  
Darrell S. Pardi ◽  
William J. Tremaine ◽  
Patricia P. Kammer ◽  
Edward V. Loftus

2019 ◽  
Vol 11 (3) ◽  
pp. 228-234 ◽  
Author(s):  
Andreas Münch ◽  
David S Sanders ◽  
Michael Molloy-Bland ◽  
A Pali S Hungin

Microscopic colitis (MC) is a treatable cause of chronic, non-bloody, watery diarrhoea, but physicians (particularly in primary care) are less familiar with MC than with other causes of chronic diarrhoea. The colon in patients with MC is usually macroscopically normal. MC can only be diagnosed by histological examination of colonic biopsies (subepithelial collagen band >10 µm (collagenous colitis) or >20 intraepithelial lymphocytes per 100 epithelial cells (lymphocytic colitis), both with lamina propria inflammation). The UK National Health Service exerts downward pressure to minimise colonoscopy referrals. Furthermore, biopsies are often not taken according to guidelines. These factors work against MC diagnosis. In this review, we note the high incidence of MC (comparable to ulcerative colitis and Crohn’s disease) and its symptomatic overlap with irritable bowel syndrome. We also highlight problems with the recommendation by National Health Service/National Institute for Health and Care Excellence guidelines for inflammatory bowel diseases that colonoscopy referrals should be based on a faecal calprotectin level of ≥100 µg/g. Faecal calprotectin is <100 µg/g in over half of individuals with active MC, building into the system a propensity to misdiagnose MC as irritable bowel syndrome. This raises important questions—how many patients with MC have already been misdiagnosed, and how do we address this silent burden? Clarity is needed around pathways for MC management; MC is poorly acknowledged by the UK healthcare system and it is unlikely that best practices are being followed adequately. There is an opportunity to identify and treat patients with MC more effectively.


Sign in / Sign up

Export Citation Format

Share Document